Industry news

Clinical trials of drugs for autoimmune diseases and cancer soon to start in Russia

GMP News

Clinical trials of about 30 new medicinal products for the treatment of cancer, autoimmune and hereditary diseases are expected to start in the Russian Federation. This was announced by the Russian Minister of Health Veronika Skvortsova at Biotechmed, a specialized conference.

Kazakhstan plans a phased introduction of regulated prices for all drugs

GMP News

The Ministry of Health of the Republic of Kazakhstan elaborated a draft Law of the Republic of Kazakhstan “On Changes and Amendments to Certain Legislative Acts of the Republic of Kazakhstan on the Issues of Circulation of Medicines and Medical Devices” in order to improve the regulation in this area and create a patient-oriented drug provision model.

Yakutia team aims to keep degenerative brain disease at bay

Marchmont Innovation News

Scientists at the North-Eastern Federal University in Yakutsk (NEFU), in Russia’s Far East, have developed a method of alleviating symptoms and slowing down the progression of spinocerebellar ataxia, or atrophy, an acute genetic brain disease that leads to dramatic motor coordination impairment and eventual shortening of a patient’s life expectancy. 

15 September 2017

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the pricing of an underwritten public offering of 9,333,334 shares of common stock for a public offering price of $3.75 per share. The gross proceeds from the offering are expected to be $35 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. 

Prevnar 13 among blockbusters industry watchers peg as tribal licensing candidates

Eric Sagonowsky / FiercePharma

Even as many on social media blasted Allergan’s licensing deal with the Saint Regis Mohawk Tribe, some industry-watchers think the tactic is bound to spread. In the wake of the potentially game-changing patent transfer, Pfizer’s Prevnar 13 is one medical product that’s been pegged as a possible cadidate for the patent protection strategy.

Cancer patients know immuno-oncology and top drugs, but lack details: study

Beth Snyder Bulik / FiercePharmaMarketing

Immuno-oncology and immunotherapy are familiar terms to cancer patients. However, when it comes to specifics on how drugs work or genetic details such as PD-1 or CTLA-4 pathways, knowledge drops off. That’s according to a new survey from Inspire of more than 800 cancer patients who use its patient engagement platform.

FDA commissioner: We need to talk about drug development costs

Ben Adams / FiercePharma

Speaking at the RAPS Regulatory Convergence conference yesterday, Gottlieb focused much of his speech on driving efficiencies into the biomedical R&D model and thinking about the traditional three phases of trials.

14 September 2017

Marinus Pharmaceuticals Announces Public Offering of Common Stock

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Russian authorities proposed to introduce liability for false drug prices

GMP News

The Russian Ministry of Health proposed to introduce administrative liability for legal entities in case of false information provided during the state registration/re-registration of maximum selling prices for the medicines included in list of vital and essential drugs (VED).

Chile interested in expanding cooperation with St. Petersburg Research Institute

GMP News

The Chilean side represented by Pablo Ortiz Diaz, the Managing Finance Director, showed interest in expanding the cooperation with St. Petersburg Research Institute of Vaccines and Serums in assessing the potential for the presence of Russian immunobiological products in the market of Chile and other countries of the region.